ASTH.NASDAQAstrana Health, INC
10-Q: Astrana Health Reports Q1 2025 Results: Revenue Jumps 53% but Net Income Declines
Sentiment:
Quarterly Report
Astrana Health's Q1 2025 revenue increased by 53% year-over-year, driven by capitation growth, while net income saw a decrease.
Worse than expectedNet income attributable to Astrana Health, Inc. decreased to $6.7 million from $14.8 million in Q1 2024.Adjusted EBITDA decreased to $36.4 million from $42.2 million in the prior year's quarter.
Summary
- Astrana Health, Inc. reported its financial results for the quarter ended March 31, 2025.
- Total revenue increased by 53% to $620.4 million, compared to $404.4 million in Q1 2024.
- Capitation revenue was a primary driver, increasing by $218.0 million due to recent acquisitions and enrollees transitioning to full risk plans.
- Net income attributable to Astrana Health, Inc. decreased to $6.7 million from $14.8 million in the same period last year.
- Operating expenses increased by 60% to $599.8 million, driven by cost of services and general and administrative expenses.
- Adjusted EBITDA decreased to $36.4 million from $42.2 million in Q1 2024.
- The company managed over 1.0 million patients through 20 risk-bearing organizations as of March 31, 2025.
- Astrana received Hart-Scott-Rodino (HSR) approval for its pending acquisition of Prospect Health, expected to close this summer.
- The company's effective income tax rate for the three months ended March 31, 2025 and 2024, was 35.2 % and 29.8 % , respectively.
Sentiment
Score: 6
Explanation: The document presents mixed sentiment. Revenue growth is positive, but declining net income and EBITDA are concerning. The pending acquisition is a potential catalyst, but integration risks remain.
Positives
- Total revenue increased by 53% year-over-year, reaching $620.4 million.
- Capitation revenue increased significantly by $218.0 million.
- The company manages healthcare services for over 1.0 million patients.
- Astrana received HSR approval for the Prospect Health acquisition, anticipated to close this summer.
Negatives
- Net income attributable to Astrana Health, Inc. decreased to $6.7 million from $14.8 million in Q1 2024.
- Adjusted EBITDA decreased to $36.4 million from $42.2 million in the prior year's quarter.
- Operating expenses rose by 60% to $599.8 million.
Risks
- The company's future performance is subject to various risk factors outlined in their annual report on Form 10-K.
- The healthcare industry is subject to complex and evolving laws and regulations, which could impact compliance and operations.
- The company's estimates and assumptions could differ materially from actual results.
- The company's success depends on maintaining relationships with providers and payers.
Future Outlook
Astrana anticipates closing the acquisition of Prospect Health this summer, pending final approvals.
Management Comments
- Astrana announced several additions to its leadership team to support continued growth and execution.
Industry Context
Astrana operates in the value-based healthcare sector, focusing on provider-centric, technology-powered, risk-bearing models. The company's performance reflects the ongoing shift towards value-based care and the increasing importance of care coordination and risk management.
Comparison to Industry Standards
- It is difficult to compare Astrana directly to industry standards without specific benchmarks for companies with similar business models.
- However, companies like Oak Street Health (acquired by CVS Health) and Alignment Healthcare also focus on value-based care for Medicare Advantage patients.
- Their financial results and growth metrics could provide some context for evaluating Astrana's performance.
- Additionally, industry reports on Medicare Advantage and managed care trends can offer insights into the broader market dynamics affecting Astrana.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Data & Analytics Officer | NA | Georgie Sam | Q1 2025 | To oversee enterprise-wide data and analytics strategy |
| Chief Accounting Officer | NA | Glenn Sobotka | Q1 2025 | To support Astrana's continued financial discipline and scalability |
| Chief People Officer | NA | Rita Pew | Q1 2025 | To help Astrana further invest in the talent and culture |
Legal Proceedings
- The Company is involved in various legal proceedings and other matters arising in the normal course of its business.
- Management does not believe the Company is a party to any legal proceedings that would have a material adverse effect on its operations.
Related Party Transactions
- The Company has various related-party transactions, including payments to board members for provider services, rent expenses, and management fees.
- These transactions are disclosed in detail in Note 13 to the condensed consolidated financial statements.
Stakeholder Impact
- Shareholders: Mixed impact due to revenue growth but declining profitability.
- Employees: Potential for growth and development with leadership changes and expansion.
- Patients: Continued access to coordinated care through the company's network.
- Providers: Opportunities to participate in value-based care arrangements.
Next Steps
- The company anticipates closing the acquisition of Prospect Health this summer.
- Astrana will continue to focus on integrating recent acquisitions and expanding its value-based care model.
Key Dates
| Date | Description |
|---|---|
| December 21, 2016 | Date of original Agreement and Plan of Merger |
| March 30, 2017 | Date of Amendment to the Agreement and Plan of Merger |
| October 17, 2017 | Date of Amendment No. 2 to the Agreement and Plan of Merger |
| March 15, 2019 | Date of Stock Purchase Agreement between Allied Physicians of California, APC-LSMA Designated Shareholder Medical Corporation, and Dr. Kevin Tyson |
| September 10, 2019 | Date of APC Business Loan Agreement with Preferred Bank amendment |
| December 31, 2019 | Date of Stock Purchase Agreement among Bright Health Company of California, Inc., the sellers party thereto, Universal Care, Inc., the seller representatives set forth therein, and Bright Health, Inc. |
| January 21, 2015 | Date of Restated Certificate of Incorporation |
| April 27, 2015 | Date of Certificate of Amendment of Restated Certificate of Incorporation |
| November 15, 2017 | Joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) |
| December 13, 2017 | Date of Certificate of Amendment of Restated Certificate of Incorporation |
| June 21, 2018 | Date of Certificate of Amendment of Restated Certificate of Incorporation |
| May 10, 2019 | Date of the Company's Quarterly Report on Form 10-Q |
| May 6, 2020 | Date of the Company's Current Report on Form 8-K |
| January 21, 2025 | Date of the Company's Current Report on Form 8-K |
| January 26, 2024 | Date of Certificate of Amendment of Restated Certificate of Incorporation |
| June 13, 2024 | Date of Certificate of Amendment of Restated Certificate of Incorporation |
| February 29, 2024 | Date of Amended and Restated By-laws |
| November 8, 2024 | Date of Asset and Equity Purchase Agreement |
| January 17, 2025 | Date of Stock Repurchase Agreement |
| January 31, 2025 | Date of Employment Agreement between Astrana Health, Inc. and Dinesh Kumar, MD |
| February 26, 2025 | Date of Second Amended and Restated Credit Agreement |
| February 27, 2025 | Date of the Company's Current Report on Form 8-K |
| March 14, 2025 | Date of the Company's Annual Report on Form 10-K |
| March 31, 2025 | End of the reported quarter |
| May 5, 2025 | Date of outstanding shares of common stock |
| May 9, 2025 | Date of report filing |
Keywords
Astrana Health, financial results, Q1 2025, capitation, revenue, net income, EBITDA, acquisition, healthcare, risk-bearing, prospect health
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.